Skip to main content
logo
Daewon Pharmaceutical Co., Ltd. (KRX:003220)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,710.00
-100.00 (-1.28%)
At close: Aug 21, 2026

Daewon Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
2,632-1,38014,21023,91731,9446,989
Depreciation & Amortization
24,59223,74720,09517,56119,36817,805
Loss (Gain) From Sale of Assets
-99.592,091-25.42-149.95-45.710.86
Asset Writedown & Restructuring Costs
945.031,2404,6714,5972,1541,111
Loss (Gain) From Sale of Investments
-13,072-10,7881,14961.5752.76870.39
Loss (Gain) on Equity Investments
-1,633-762.1-704.2-509.42-860.08-382.62
Provision & Write-off of Bad Debts
347.22197.33-204.13230.88887.59-250.26
Other Operating Activities
11,1859,39617,84010,63813,24013,054
Change in Accounts Receivable
12,308-3,963-2,504-7,949-11,075-11,278
Change in Inventory
9,05014,168-6,642-15,837-23,989-4,075
Change in Accounts Payable
-6,06010,0681,041938.612,107-1,445
Change in Income Taxes
1.081.323.21-2.035.05-0.32
Change in Other Net Operating Assets
-22,144-1,909-18,89418,239-8,07514.07
Operating Cash Flow
18,18242,31330,03551,73426,41322,413
Operating Cash Flow Growth
-77.30%40.88%-41.94%95.86%17.85%-10.17%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-23,354-29,801-34,864-12,289-8,009-4,104
Sale of Property, Plant & Equipment
476.02484.22778.66204.25504.445.16
Cash Acquisitions
-322.71--7.62---14,602
Sale (Purchase) of Intangibles
-14,797-12,330-18,218-8,322-5,357-7,603
Investment in Securities
-1,0166,083-12,241-893.53-9,055-16,256
Other Investing Activities
30,36224,52620,882-47,3311,520562.08
Investing Cash Flow
-193.17-11,417-42,975-68,267-20,775-41,615

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-33,66960,42120,08130027,069
Long-Term Debt Issued
-29,60842,00022,0003,35245,920
Total Debt Issued
146,86263,277102,42142,0813,65272,989
Short-Term Debt Repaid
--22,469-45,000-234.39-468.76-10,063
Long-Term Debt Repaid
--27,675-42,958-10,666-10,062-9,479
Total Debt Repaid
-141,924-50,144-87,958-10,900-10,530-19,541
Net Debt Issued (Repaid)
4,93813,13314,46331,181-6,87853,448
Issuance of Common Stock
---106.64-210.31
Repurchase of Common Stock
-----6,171-85.84
Dividends Paid
-5,358-6,430-6,359-7,340-4,120-3,140
Other Financing Activities
-7,236-7,632-8,402-4,434-3,241-1,906
Financing Cash Flow
-7,656-929.26-297.8119,513-20,41148,527

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
608.72172.75312.2232.0945.2640.01
Miscellaneous Cash Flow Adjustments
-----1,893
Net Cash Flow
10,94130,140-12,9263,013-14,72731,258

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-5,17212,512-4,82939,44618,40518,309
Free Cash Flow Growth
---114.32%0.52%34.58%
Free Cash Flow Margin
-0.84%2.07%-0.81%7.49%3.84%5.17%
Free Cash Flow Per Share
-240.76583.77-226.831821.12841.34862.87
Levered Free Cash Flow
-2,09211,631-28,2022,59010,19614,843
Unlevered Free Cash Flow
2,13316,144-22,3865,47412,49816,142

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
7,1297,5266,5134,4213,2301,858
Cash Income Tax Paid
9,00512,5844,8215,2117,5228,922
Change in Working Capital
-6,84518,365-26,996-4,611-41,027-16,784